The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Texas MPN Workshop 2022 | The management of advanced phase MPNs

Name: The management of advanced phase MPNs
Uploaded: 2022-08-26T00:00:00Z
Duration: 2 min 42 s
Description: Abdulraheem Yacoub, MD, The University of Kansas, Westwood, KS, shares some insights into the management of accelerated phase myeloproliferative neoplasms (MPN-AP) and the need to design and conduct more clinical trials for patients with advanced disease. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Abdulraheem Yacoub • 26 Aug 2022

Texas MPN Workshop 2022

Leukemia Myeloproliferative Neoplasms

Abdulraheem Yacoub, MD, The University of Kansas, Westwood, KS, shares some insights into the management of accelerated phase myeloproliferative neoplasms (MPN-AP) and the need to design and conduct more clinical trials for patients with advanced disease. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Advisory role: Incyte, CTI Pharma , Pharmaessentia, Pfizer, Novartis, ACCELERON PHARMA, Agios ABBVIE, Apellis, Gilead, Notable Labs. Research Support: CTI Pharma, Stemline Therapeutics